Csenge Advisory Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $699K | Sell |
9,778
-278
| -3% | -$19.9K | 0.04% | 342 |
|
|
2025
Q1 | $584K | Sell |
10,056
-402
| -4% | -$23.3K | 0.03% | 363 |
|
|
2024
Q4 | $900K | Sell |
10,458
-17,649
| -63% | -$1.52M | 0.05% | 285 |
|
|
2024
Q3 | $3.37M | Buy |
28,107
+585
| +2% | +$70.2K | 0.18% | 103 |
|
|
2024
Q2 | $3.93M | Buy |
27,522
+4,254
| +18% | +$607K | 0.22% | 88 |
|
|
2024
Q1 | $2.99M | Buy |
23,268
+3,694
| +19% | +$474K | 0.17% | 111 |
|
|
2023
Q4 | $2.02M | Buy |
19,574
+9,817
| +101% | +$1.02M | 0.13% | 135 |
|
|
2023
Q3 | $887K | Buy |
9,757
+3,159
| +48% | +$287K | 0.06% | 231 |
|
|
2023
Q2 | $534K | Buy |
6,598
+2,462
| +60% | +$199K | 0.04% | 351 |
|
|
2023
Q1 | $329K | Sell |
4,136
-322
| -7% | -$25.6K | 0.02% | 446 |
|
|
2022
Q4 | $302K | Sell |
4,458
-626
| -12% | -$42.4K | 0.02% | 461 |
|
|
2022
Q3 | $253K | Buy |
5,084
+190
| +4% | +$9.46K | 0.02% | 508 |
|
|
2022
Q2 | $273K | Sell |
4,894
-38
| -0.8% | -$2.12K | 0.02% | 469 |
|
|
2022
Q1 | $274K | Buy |
4,932
+118
| +2% | +$6.56K | 0.02% | 516 |
|
|
2021
Q4 | $203K | Sell |
4,814
-326
| -6% | -$13.7K | 0.02% | 533 |
|
|
2021
Q3 | $246K | Buy |
5,140
+326
| +7% | +$15.6K | 0.02% | 509 |
|
|
2021
Q2 | $203K | Buy |
+4,814
| New | +$203K | 0.02% | 536 |
|
|
2018
Q4 | – | Sell |
-86
| Closed | -$1K | – | 1056 |
|
|
2018
Q3 | $1K | Buy |
+86
| New | +$1K | ﹤0.01% | 898 |
|